Taofeek Owonikoko
Hematology & Oncology · Pittsburgh, PANPI 1578770871
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $264,058 of the $346,380 with a category attached, or 76.2%. It is spread thinly across 35 manufacturers, the largest accounting for just 18.9%. Reporting peaked in 2019 at $129,037 and has fallen 83.0% since, to $21,937 in 2025. Among hematology & oncology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 258 payments — averaging $1342.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$65K
- Amgen$34K
- Astrazeneca UK Limited$29K
- Boehringer Ingelheim International GmbH$24K
- Novartis$21K
- Gilead$20K
- plus $153K from 29 others
Across 390 payments — averaging $24,112 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$2.8M
- Y-mabs Therapeutics, Inc.$1.7M
- Amgen$1M
- Novartis$811K
- AstraZeneca$718K
- Merck$486K
- plus $1.8M from 20 others
What the payments were for
- Consulting fees$264,05876%
- Speaking & faculty fees$13,0684%
- Travel & lodging$62,63318%
- Food & beverage$5,4712%
- Education$1,1500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 57 | $65,358 |
| Amgen | 14 | $33,963 |
| Astrazeneca UK Limited | 18 | $29,350 |
| Boehringer Ingelheim International GmbH | 13 | $23,716 |
| Novartis | 14 | $20,655 |
| Gilead | 6 | $20,239 |
| E.r. Squibb & Sons, L.L.C. | 14 | $15,219 |
| Jazz Pharmaceuticals Inc. | 5 | $14,718 |
| Daiichi Sankyo Inc. | 17 | $14,305 |
| Merck | 10 | $14,041 |
| Astrazeneca AB | 10 | $9,945 |
| Bayer | 12 | $9,502 |
| AbbVie | 6 | $9,089 |
| Regeneron | 15 | $8,346 |
| Eisai Inc. | 11 | $8,331 |
| Puma Biotechnology, Inc. | 4 | $7,782 |
| Ipsen Biopharmaceuticals, Inc | 1 | $6,200 |
| Eli Lilly | 3 | $5,950 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 2 | $4,201 |
| Genentech USA, Inc. | 6 | $4,157 |
| Janssen Scientific Affairs, LLC | 5 | $4,069 |
| EMD Serono, Inc. | 1 | $3,000 |
| F. Hoffmann-la Roche AG | 2 | $2,744 |
| Merck Kgaa | 1 | $2,400 |
| Ipsen Bioscience Inc. | 1 | $2,000 |
| Janssen Global Services, LLC | 1 | $1,890 |
| Exelixis Inc. | 1 | $1,650 |
| Catalyst Pharmaceuticals, Inc. | 1 | $1,500 |
| Beigene, Ltd. | 1 | $1,322 |
| Boehringer Ingelheim | 1 | $183 |
| Eagle Pharmaceuticals, Inc. | 1 | $149 |
| Johnson & Johnson | 1 | $113 |
| Genentech, Inc. | 1 | $105 |
| Comsort, Inc | 1 | $100 |
| Genmab U.S., Inc. | 1 | $88 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$346,380 in reported general payments places this provider in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Pittsburgh
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Alexander BarsoukPittsburgh$674K
- Hashem YounesPittsburgh$435K
- Jason LukePittsburgh$300K
- Ahmad TarhiniPittsburgh$216K
- Diwakar DavarPittsburgh$104K
- Jing Zhou HouPittsburgh$78K
- Vikram GorantlaPittsburgh$62K
- Stanley MarksPittsburgh$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.